A randomized controlled trial for improving QOL (Quality of Life) of healthy adults with knee joint pain.

A randomized controlled trial for improving QOL (Quality of Life) of healthy adults with knee joint pain. - A randomized controlled trial for improving QOL (Quality of Life) of healthy adults with knee joint pain.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019995

Enrollment

Registered

2016-11-30

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Duration: 8 weeks Test material: Soft capsule contained 20mg of paprika pigment extract 2 capsules per day Duration: 12 weeks Test material: placebo soft capsule 2 capsules per day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) Healthy adults with knee joint pain. b) Males and females aged 45 to 69 years old.

Exclusion criteria

Exclusion criteria: a) Persons who have previous medical history of malignant tumor, or heart failure and/or myocardial infarction. b) Patients being treated for at least one of following diseases: atrial fibrillation, cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, and/or other chronic disease. c) Persons who take medicines, herbal medicines, or dietary supplements. d) Persons who are allergic to medicines or foods related to the test material of this trial. e) Smokers f) Pregnant women, lactating women, or women who plan to get pregnant during the trial period. g) Persons who have been enrolled in the other clinical trials within last 3 months before the agreement for the participation to this trial h) Persons who often take Satsuma mandarin oranges (Citrus unshiu Marc.) and/or their processed foods. i) Persons judged not suitable to participate in this trial by physician.

Design outcomes

Primary

Measure	Time frame
Questionnaires (JKOM) (0, 4, 8 week)	—

Secondary

Measure	Time frame
Serum hs-CRP, Serum IL-6, Serum TNF-alpha (0, 8 week)	—

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026